Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian P Gee

Cytotherapy

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Cytotherapy|October 8, 2014
CD34 measurement: setting standardsAdrian P Gee
Cytotherapy|March 3, 2011
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphomaCatherine M Bollard, Stephen Gottschalk, M Helen Huls, et al.
Cytotherapy|December 17, 2011
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplantUluhan Sili, Ann M Leen, Juan F Vera, et al.
Cytotherapy|September 15, 2022
Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signalingMaria da Graça Cabreira, Xiaohong Wang, Andre Critsinelis, et al.
Cytotherapy|October 1, 2015
Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potencyBahey Salem, Samantha Miner, Nancy F Hensel, et al.
Cytotherapy|December 3, 2014
A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppressionDebra D Bloom, John M Centanni, Neehar Bhatia, et al.
Cytotherapy|March 14, 2013
Manufacturing mesenchymal stromal cells for phase I clinical trialsPatrick J Hanley, Zhuyong Mei, Maria da Graca Cabreira-Hansen, et al.
Cytotherapy|January 19, 2010
CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicineDavid H McKenna, Sheryl Adams, Darin Sumstad, et al.
Cytotherapy|June 8, 2010
Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experienceAdrian P Gee, Sara Richman, April Durett, et al.
Cytotherapy|May 1, 2010
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experienceConrad Russell Cruz, Patrick J Hanley, Hao Liu, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cytotherapy|October 8, 2014
CD34 measurement: setting standardsAdrian P Gee
Cytotherapy|March 3, 2011
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphomaCatherine M Bollard, Stephen Gottschalk, M Helen Huls, et al.
Cytotherapy|December 17, 2011
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplantUluhan Sili, Ann M Leen, Juan F Vera, et al.
Cytotherapy|September 15, 2022
Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signalingMaria da Graça Cabreira, Xiaohong Wang, Andre Critsinelis, et al.
Cytotherapy|October 1, 2015
Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potencyBahey Salem, Samantha Miner, Nancy F Hensel, et al.
Cytotherapy|December 3, 2014
A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppressionDebra D Bloom, John M Centanni, Neehar Bhatia, et al.
Cytotherapy|March 14, 2013
Manufacturing mesenchymal stromal cells for phase I clinical trialsPatrick J Hanley, Zhuyong Mei, Maria da Graca Cabreira-Hansen, et al.
Cytotherapy|January 19, 2010
CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicineDavid H McKenna, Sheryl Adams, Darin Sumstad, et al.
Cytotherapy|June 8, 2010
Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experienceAdrian P Gee, Sara Richman, April Durett, et al.
Cytotherapy|May 1, 2010
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experienceConrad Russell Cruz, Patrick J Hanley, Hao Liu, et al.
Pageof 2